CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy

ROCKVILLE, Md., June 17, 2019 -- (Healthcare Sales & Marketing Network) -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company that is focusing on developing and accelerating the launch of innovative therapeutics and pharmaceutical... Biopharmaceuticals, Oncology, Licensing, Acquisitions CASI Pharmaceuticals, Juventas Cell Therapy, T-cell therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news